chr7-116782014-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -17 ACMG points: 0P and 17B. BP4_StrongBP6_Very_StrongBP7BS1
The NM_000245.4(MET):c.3549C>T(p.Gly1183Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000126 in 1,613,620 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.00068 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000068 ( 1 hom. )
Consequence
MET
NM_000245.4 synonymous
NM_000245.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.865
Genes affected
MET (HGNC:7029): (MET proto-oncogene, receptor tyrosine kinase) This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -17 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.48).
BP6
Variant 7-116782014-C-T is Benign according to our data. Variant chr7-116782014-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 215485.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr7-116782014-C-T is described in Lovd as [Likely_benign]. Variant chr7-116782014-C-T is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=0.865 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.000683 (104/152284) while in subpopulation AFR AF= 0.00245 (102/41550). AF 95% confidence interval is 0.00207. There are 0 homozygotes in gnomad4. There are 48 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MET | NM_000245.4 | c.3549C>T | p.Gly1183Gly | synonymous_variant | 18/21 | ENST00000397752.8 | NP_000236.2 | |
MET | NM_001127500.3 | c.3603C>T | p.Gly1201Gly | synonymous_variant | 18/21 | NP_001120972.1 | ||
MET | NM_001324402.2 | c.2259C>T | p.Gly753Gly | synonymous_variant | 17/20 | NP_001311331.1 | ||
MET | XM_011516223.2 | c.3606C>T | p.Gly1202Gly | synonymous_variant | 19/22 | XP_011514525.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MET | ENST00000397752.8 | c.3549C>T | p.Gly1183Gly | synonymous_variant | 18/21 | 1 | NM_000245.4 | ENSP00000380860.3 | ||
MET | ENST00000318493.11 | c.3603C>T | p.Gly1201Gly | synonymous_variant | 18/21 | 1 | ENSP00000317272.6 | |||
MET | ENST00000436117.3 | n.*1154C>T | non_coding_transcript_exon_variant | 17/20 | 1 | ENSP00000410980.2 | ||||
MET | ENST00000436117.3 | n.*1154C>T | 3_prime_UTR_variant | 17/20 | 1 | ENSP00000410980.2 |
Frequencies
GnomAD3 genomes AF: 0.000697 AC: 106AN: 152166Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
106
AN:
152166
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000197 AC: 49AN: 248736Hom.: 0 AF XY: 0.0000889 AC XY: 12AN XY: 134958
GnomAD3 exomes
AF:
AC:
49
AN:
248736
Hom.:
AF XY:
AC XY:
12
AN XY:
134958
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000677 AC: 99AN: 1461336Hom.: 1 Cov.: 31 AF XY: 0.0000564 AC XY: 41AN XY: 726986
GnomAD4 exome
AF:
AC:
99
AN:
1461336
Hom.:
Cov.:
31
AF XY:
AC XY:
41
AN XY:
726986
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000683 AC: 104AN: 152284Hom.: 0 Cov.: 33 AF XY: 0.000645 AC XY: 48AN XY: 74468
GnomAD4 genome
AF:
AC:
104
AN:
152284
Hom.:
Cov.:
33
AF XY:
AC XY:
48
AN XY:
74468
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 11, 2015 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, criteria provided, single submitter | curation | Sema4, Sema4 | Dec 15, 2020 | - - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
MET-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 09, 2024 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Renal cell carcinoma Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | - - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 14, 2021 | - - |
Papillary renal cell carcinoma type 1 Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at